文献速递消化道肿瘤与早癌

阿司匹林联合SSRI与降低结直肠癌风险相关:巢式病例对照研究

Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

该巢式病例对照研究基于瑞典全国登记数据,纳入24,786例结直肠癌病例和74,358名对照,评估阿司匹林与SSRI单用或联用与结直肠癌风险的关系。结果显示两者单用均与较低风险相关,联用调整OR为0.77(95%CI 0.67-0.89),低于阿司匹林单用(0.91)或SSRI单用(0.93),加性交互显著(RERI -0.07,P<0.001)。

要点

  • 阿司匹林与SSRI联用与结直肠癌风险降低相关,调整OR 0.77(95%CI 0.67-0.89)。
  • 联用风险低于阿司匹林单用(OR 0.91)或SSRI单用(OR 0.93)。
  • 加性交互显著(RERI -0.07,P<0.001),呈剂量依赖模式。

核心结论

  • 阿司匹林与SSRI单用或联用均与结直肠癌风险降低相关,联用关联更强。

研究设计与样本

  • 巢式病例对照研究,使用瑞典全国登记数据,纳入24,786例结直肠癌病例和74,358名对照。
  • 按出生年份和性别进行 incidence-density sampling 随机匹配,采用条件 logistic 回归计算 OR 和 95%CI。

主要发现

  • 阿司匹林单用调整OR 0.91(95%CI 0.87-0.97),SSRI单用调整OR 0.93(95%CI 0.86-1.00)。
  • 阿司匹林与SSRI联用调整OR 0.77(95%CI 0.67-0.89),低于任一单用。
  • 加性交互显著,RERI -0.07(P<0.001);乘性交互未观察到显著交互。
  • 阿司匹林和SSRI与结直肠癌的负相关呈剂量依赖模式。

临床怎么用

  • 联用阿司匹林与SSRI可能带来更强结直肠癌化学预防关联,但需进一步研究确认机制和临床推荐可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chemoprevention against colorectal cancer (CRC) is greatly needed. As the development of CRC involves multiple dysfunctional pathways, it is thus reasonable to combine some agents that address several pathways to achieve better chemoprotection. We aimed to explore whether the use of aspirin and selective serotonin reuptake inhibitors (SSRIs)-either as monotherapy or combined-can have a clinical benefit against CRC. METHODS: We performed a nested case-control study using nationwide Swedish registers. We recruited 24,786 CRC cases and randomly matched to 74,358 controls conditional on birth year and sex using incidence-density sampling. The conditional logistic regression model was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Additive interaction was calculated as the relative excess risk for interaction, and multiplicative interaction was calculated by including a product term in the regression model. RESULTS: Both aspirin and SSRIs monotherapy were negatively associated with CRC risk, but the combined use of aspirin and SSRIs was associated with an even lower CRC risk (adjusted OR, 0.77, 95% CI, 0.67-0.89) than aspirin monotherapy (adjusted OR, 0.91, 95% CI, 0.87-0.97) or SSRI monotherapy (adjusted OR, 0.93, 95% CI, 0.86-1.00). A significant interaction was observed at the additive scale with a relative excess risk for interaction of -0.07 (P < 0.001), whereas no interaction was noted on the interactive scale. The inverse associations of CRC with aspirin and SSRIs showed a dose-dependent pattern. DISCUSSION: This study suggests that the use of aspirin and SSRIs-either as monotherapy or combined-was associated with a reduced risk of CRC. The stronger chemoprevention of combined use of aspirin and SSRIs is innovative and calls for further studies to confirm the underlying mechanisms and the plausibility of clinical recommendation.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Zhang N, Sundquist J, Sundquist K, et al. Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study. Am J Gastroenterol. 2021. PMID: 33661146. doi:10.14309/ajg.0000000000001192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。